Headquartered in Chicago, Illinois, Ventas, Inc. (VTR) is a leading healthcare-focused real estate investment trust (REIT) with a diversified portfolio of approximately 1,400 properties across the U.S., Canada, and the U.K. The company, currently valued at $29.7 billion by market cap, specializes in senior housing, medical office buildings, hospitals, and life sciences facilities.
The healthcare REIT is expected to announce its fiscal 2025 second-quarter earnings after the market closes on Wednesday, Jul. 30. Ahead of the event, analysts expect VTR to report an FFO of $0.85 per share on a diluted basis, up 6.3% from $0.80 per share in the year-ago quarter. The company has beaten or matched Wall Street’s FFO estimates in its last four quarterly reports.
For the current year, analysts expect VTR to report FFO of $3.45 per share, up 8.2% from $3.19 in fiscal 2024. Its FFO is expected to rise 7.8% year over year to $3.72 in fiscal 2026.
VTR shares have surged 24.7% over the past 52 weeks, outperforming the S&P 500 Index’s ($SPX) 14.5% gains and the Real Estate Select Sector SPDR Fund’s (XLRE) 3.7% gains over the same time frame.
On April 30, Ventas reported first-quarter results, and its shares fell 6.5% in the following trading session due to concerns over share dilution and alignment of future guidance with capital-raising plans. The company continued to benefit from the long-term senior housing growth trend, posting a robust 13.6% year-over-year increase in same-store cash NOI and a 13.2% rise in total revenue to $1.4 billion, surpassing Wall Street expectations. Moreover, NFFO per share rose 7.7% to $0.84.
Analysts’ consensus opinion on VTR stock is very bullish, with a “Strong Buy” rating overall. Out of 19 analysts covering the stock, 14 advise a “Strong Buy” rating, two suggest a “Moderate Buy,” and three give a “Hold.” VTR’s average analyst price target is $75.39, indicating a potential upside of 13.5% from the current levels.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.